Mesoblast (MESO) Change in Receivables (2016 - 2023)
Mesoblast (MESO) posted quarterly Change in Receivables of $9000.0 for Q1 2023, down 97.81% year-on-year from $411000.0 in Q1 2022, and up 100.71% on a QoQ basis from -$1.3 million in Q4 2022.
Mesoblast (MESO) Change in Receivables (2016 - 2023) Analysis & Trends
Mesoblast (MESO) has reported Change in Receivables for 8 consecutive years, with $9000.0 the latest figure, recorded in Q1 2023.
- Quarterly Change in Receivables fell 97.81% year-over-year to $9000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $499000.0 (up 132.79% YoY) and the FY2022 annual result came in at $140000.0, up 108.05% from the prior year.
- Change in Receivables climbed to $9000.0 in Q1 2023 per MESO's latest filing, from -$1.3 million in the prior quarter.
- Over the last five years, Change in Receivables for MESO reached as high as $14.8 million in Q4 2019 and fell as low as -$15.4 million in Q3 2019.
- A 5-year average of -$97294.1 and a median of $9000.0 in 2023 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2021 — Change in Receivables soared 551.56% — and 2022, when it slumped 197.64%.
- Year by year, Change in Receivables stood at $14.8 million in 2019, then sank by 105.81% to -$858000.0 in 2020, then jumped by 50.58% to -$424000.0 in 2021, then sank by 197.64% to -$1.3 million in 2022, then soared by 100.71% to $9000.0 in 2023.
- According to Business Quant data, Change in Receivables over the past three periods registered $9000.0, -$1.3 million, and $519000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 9,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Dec 31, 2022 | -1.26 Mn |
| Dec 31, 2022 | -1.26 Mn |
| Sep 30, 2022 | 519,000.00 |
| Sep 30, 2022 | 519,000.00 |
| Jun 30, 2022 | 1.23 Mn |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 411,000.00 |
| Mar 31, 2022 | 411,000.00 |
| Dec 31, 2021 | -424,000.00 |
| Dec 31, 2021 | -424,000.00 |
| Sep 30, 2021 | -1.08 Mn |
| Sep 30, 2021 | -1.08 Mn |
| Jun 30, 2021 | -429,000.00 |
| Jun 30, 2021 | -429,000.00 |
| Mar 31, 2021 | 417,000.00 |
| Mar 31, 2021 | 417,000.00 |
| Dec 31, 2020 | -858,000.00 |
| Dec 31, 2020 | -858,000.00 |